Skip to main content
Pay Bill Portals

Why Regular MRD Testing Matters for Ovarian Cancer Patients

Published Date

Unlike traditional imaging, which can only detect larger tumors, MRD testing identifies tiny fragments of cancer DNA circulating in the blood—often months before recurrence may show up on a scan. This early insight allows patients and their care teams to act sooner, when the disease may be more treatable.

Minimal Residual Disease (MRD) testing, like Signatera, is transforming how ovarian cancer is managed—especially for patients who are:

  • Post-surgery: To detect any remaining cancer cells and determine if additional therapy is needed.
  • In remission: To identify molecular recurrence before it appears on scans or causes symptoms.
  • Undergoing treatment: To evaluate how well therapy is working and guide adjustments in real time.

The Emotional and Clinical Benefits of MRD Testing

Waiting between scans can be emotionally draining. MRD testing with Signatera offers a proactive way to stay informed and engaged in your care.

  • Reduces uncertainty: Knowing whether cancer DNA is present or not helps patients feel more in control.
  • Guides treatment decisions: Supports oncologists in determining whether additional treatment is needed or if current therapies are effective.
  • Provides peace of mind: A negative MRD result reinforces that no molecular recurrence has been detected.

If you’re an ovarian cancer survivor, MRD testing can be an essential tool in your ongoing care. Talk to your doctor about whether Signatera MRD testing could help you stay ahead of recurrence and make more informed treatment decisions.